The TECHLAB® H. PYLORI QUIK CHEK™ test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette. It is intended for use with human fecal specimens to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment. The test can be used with unpreserved fecal specimens and fecal specimens preserved in transport media from patients suspected of H. pylori infection. Testing of patients to demonstrate loss of H. pylori antigen following treatment should be performed no sooner than 4 weeks after completion of the treatment regimen. Test results should be taken into consideration by the physician in conjunction with the patient history and symptoms.

Device Description

The H. PYLORI QUIK CHEK™ test utilizes antibodies specific for H. pylori antigen. The Membrane Device contains a Reaction Window with two vertical lines of immobilized antibodies. The test line ("T") contains antibodies specific for H, pylori antigen. The ("C") contains antibodies to horseradish peroxidase (HRP). The Conjugate consists of antibodies to H. pylori antigen coupled to horseradish peroxidase. To perform the test, the sample is added to a tube containing a mixture of Diluent and Conjugate. The diluted sample-conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, any H. pylori antigen in the sample binds to the antibody-peroxidase conjugate. The antigen-antibody-peroxidase complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-H. pylori antigen antibodies in the test line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After a 10-minute incubation period, the Reaction Window is examined visually for the appearance of vertical blue lines on the "C" and "T" sides of the Reaction Window. A blue line on the "T" side of the Reaction Window indicates a positive result. A positive "C" reaction, indicated by a vertical blue line on the "C" side of the Reaction Window, confirms that the sample and reagents were added correctly, the reagents were active at the time of performing the assay, and that the sample migrated properly through the Membrane Device. It also confirms the reactivity of the other reagents associated with the assay.

AI/ML Overview

Here's an analysis of the acceptance criteria and study data for the H. PYLORI QUIK CHEK™ device:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are not explicitly stated as distinct numerical targets (e.g., "sensitivity must be >90%"). Instead, the document presents the performance data and implies these values are acceptable for demonstrating substantial equivalence. The key performance metrics are Sensitivity and Specificity compared to a Composite Reference Method (CRM) for initial diagnosis, and Sensitivity for post-therapy. Also included are agreement rates from a retrospective study against an FDA-cleared ELISA, and analytical sensitivity (Limit of Detection).

Acceptance Criteria (Implied from Study Results for Substantial Equivalence)	Reported Device Performance
Initial Diagnosis (vs. CRM)
Sensitivity: To demonstrate accurate detection of H. pylori infection.	97.0% (95% CI: 84.7% - 99.5%)
Specificity: To demonstrate accurate identification of absence of H. pylori.	100.0% (95% CI: 95.9% - 100.0%)
Post-Therapy (vs. CRM)
Sensitivity: To demonstrate accurate detection of H. pylori persistence post-treatment.	100.0% (95% CI: 70.1% - 100.0%)
Retrospective Study (vs. FDA Cleared Commercial ELISA)
Positive Agreement: To demonstrate consistent positive results with predicate.	98.9% (95% CI: 94.2% - 99.8%)
Negative Agreement: To demonstrate consistent negative results with predicate.	97.2% (95% CI: 92.0% - 99.0%)
Analytical Sensitivity (Limit of Detection)	LoD for H. pylori antigen: 16.08 ng/mL in fecal matrix (0.24 ng/test). LoD in Cary Blair media: 13.01 ng/mL (0.20 ng/test). LoD in C&S media: 19.96 ng/mL (0.31 ng/test).
Reproducibility	100% overall percent agreement across different locations, technicians, and kit lots.
Analytical Specificity (Cross Reactivity)	No interference observed with listed common intestinal organisms and viruses.
Inclusivity	All tested H. pylori strains (including ATCC 700392, ATCC 43526, ATCC 700824, JP26, ATCC 43504, ATCC 43579) generated a positive result.
Interfering Substances	No effect on positive results from listed substances at indicated concentrations.
Prozone Effect	No overall prozone effect observed; elevated antigen levels did not affect detection.

2. Sample Size Used for the Test Set and Data Provenance

Initial Diagnosis & Post-Therapy Study:
- Sample Size: 122 patients for initial diagnosis, 9 samples for post-therapy.
- Data Provenance: The study was conducted at 6 independent sites. It involved patients "undergoing endoscopy as part of routine care," suggesting prospective enrollment of clinical samples. The country of origin is not explicitly stated, but given the FDA submission, it is likely the US.
Retrospective Sample Study:
- Sample Size: 200 samples (94 positive and 106 negative by the commercial ELISA).
- Data Provenance: Retrospective study. Country of origin not specified.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Initial Diagnosis & Post-Therapy Study:
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified. The ground truth was a Composite Reference Method (CRM) consisting of "rapid urease and histology of the biopsy samples." These methods are typically performed and interpreted by pathologists and gastroenterologists/endoscopists, but the specific number or qualifications of individuals involved in the CRM determination are not detailed.
Retrospective Sample Study:
- Number of Experts: Not applicable, as ground truth was established by an "FDA cleared commercial ELISA."
- Qualifications of Experts: Not applicable.

4. Adjudication Method for the Test Set

Initial Diagnosis & Post-Therapy Study: The document states "A composite reference method (CRM) comparison was used in the evaluation consisting of rapid urease and histology of the biopsy samples." This implies a combined clinical assessment, but the specific adjudication method (e.g., how discrepancies between rapid urease and histology were resolved, or if multiple readings were combined) is not detailed.
Retrospective Sample Study: Adjudication was not involved as the comparison was against a single FDA-cleared commercial ELISA. PCR was used to further investigate discordant results, but this was for understanding discrepancies, not for establishing initial ground truth.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, an MRMC comparative effectiveness study was not done. This study focuses on the standalone performance of the device compared to a reference method, not on how human readers' performance improves with or without the device. The H. PYLORI QUIK CHEK™ is a laboratory test, not an AI-assisted diagnostic tool for human interpretation.

6. Standalone Performance Study

Yes, a standalone performance study was done. The entire clinical performance section (Initial Diagnosis, Post-Therapy) and the retrospective sample study describe the performance of the H. PYLORI QUIK CHEK™ test on its own, producing a qualitative (positive/negative) result, against an established ground truth or cleared predicate device. This is the standalone performance of the algorithm/device.

7. Type of Ground Truth Used

Initial Diagnosis & Post-Therapy Study: Composite Reference Method (CRM) consisting of rapid urease and histology of biopsy samples.
Retrospective Sample Study: An FDA cleared commercial ELISA. Discordant results were further investigated using H. pylori DNA amplification with PCR.

8. Sample Size for the Training Set

The document does not explicitly mention a training set or details about its size. This is a diagnostic device (an enzyme immunoassay), not a software or AI algorithm that typically requires a distinct training phase on a dataset. The development of such a device involves optimizing reagents and protocols, which is a different process than machine learning algorithm training.

9. How the Ground Truth for the Training Set Was Established

As a distinct "training set" for an algorithm is not described, the method for establishing ground truth for such a set is not applicable/not provided in this document. The device's components (antibodies, reagents) would have been developed and validated through internal R&D processes, likely using characterized H. pylori samples and controls, but this isn't presented as a formal "training set" in the context of this 510(k) summary.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square and the words "U.S. Food & Drug Administration".

August 21, 2018

TECHLAB. Inc. Donna Link Director Regulatory and Compliance 2001 Kraft Drive Corporate Research Center Blacksburg, Virginia 24060-6358

Re: K181379

Trade/Device Name: H. Pylori Quik Chek Regulation Number: 21 CFR 866.3110 Regulation Name: Campylobacter fetus serological reagents Regulatory Class: Class I Product Code: LYR Dated: May 23, 2018 Received: May 24, 2018

Dear Donna Link:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrl/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Ribhi Shawar -S
For

Uwe Scherf, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K181379

Device Name H. PYLORI QUIK CHEK

Indications for Use (Describe)

The TECHLAB H. PYLORI QUIK CHEK™ test is a rapid membrane enzyme immunoassay for the qualitative detection of Helicobacter pylori specific antigen in a single use cassette. It is intended for use with human fecal specimens to aid in the diagnosis of H. pylori infection and to demonstrate loss of H. pylori antigen following treatment. The test can be used with unpreserved fecal specimens and fecal specimens preserved in transport media from patients suspected of H. pylori infection. Testing of patients to demonstrate loss of H. pylori antigen following treatment should be performed no sooner than 4 weeks after completion of the treatment regimen. Test results should be taken into consideration by the physician in conjunction with the patient history and symptoms.

Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)	☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

H. PYLORI QUIK CHEK™ 510(k) SUMMARY

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92.

Applicant/Contact Information:

Date Prepared:	August 16, 2018
Name:	TECHLAB, Inc.
Address:	2001 Kraft DriveCorporate Research CenterBlacksburg, VA 24060 USA

Contact Person:	Donna T. Link
Phone Number:	540-953-1664
Email:	dlink@techlab.com

1.1 Manufacturing Facility Address

TECHLAB, Inc. 20 Corporate Drive Radford, VA 24141 USA

1.2 Product and Trade Name of the Device

H. PYLORI QUIK CHEK™

1.3 Common Name or Classification Name

H. pylori detection test

1.4 Classification and Regulation

Class I 21 CFR 866.3110; Campylobacter fetus serological reagents

1.5 Product Code

LYR – Campylobacter pylori

1.6 Panel

83 Microbiology

1.7 Reason for Premarket Notification

The development of a new rapid membrane enzyme immunoassay for the qualitative detection of H. pylori in a single use cassette.

{4}------------------------------------------------

Intended Use

Caution: U.S. Federal Law restricts this device to sale by or on the order of a physician

Explanation

It is estimated that half of the global population is infected with H. pylori. The majority of those infected remain asymptomatic and do not require treatment (colonized individuals). A minority of infected individuals develop gastritis, and a fraction of those further develop gastric ulcers or gastric cancer. The diagnosis of H. pylori infection is endoscopy with biopsy - the biopsied tissue is tested for the presence of H. pylori by culture, histology, or rapid urease test. Under current guidelines, endoscopy is still recommended for the diagnosis of H. pylori infection in patients with alarm symptoms (e.g. GI bleeding, sudden weight loss, excessive vomiting, anemia), or patients over the age of 55. However, for younger patients not exhibiting alarm symptoms, non-invasive tests such as the urea breath test (UBT) or fecal antigen test are recommended for diagnosis of H. py/ori infection. Following completion of a treatment regimen of antibiotics and a proton pump inhibitor (PPI), it is recommended that patients be tested to verify eradication of H. pylori infection. Serum antibody tests are also available, but these are unable to distinguish between past and current infection. By detecting antigen present in fecal specimens, the H. PYLORI QUIK CHEK™ test allows for the non-invasive detection of H. pylori when endoscopy is not required.

Device Description

{5}------------------------------------------------

Materials Provided

. Membrane Devices - 25 pouches, each pouch contains 1 device
Conjugate (2.5 mL) Antibody specific for H. pylori antigen coupled to horseradish . peroxidase in a buffered protein solution
Diluent (22 mL) Buffered protein solution with black graduated dropper assembly .
Positive Control (2 mL) H. pylori antigen in a buffered protein solution .
Substrate (3.5 mL) Solution containing tetramethylbenzidine ●
Wash Buffer (12 mL) Buffered solution with white graduated dropper assembly ●
Disposable plastic pipettes (50) Graduated at 25 µL, 100 µL, 200 µL, 300 µL, 400 µL and . 500 µL
. Wooden applicator sticks (50)

The predicate device (ImmunoCard STAT!® HpSA) and the H. PYLORI QUIK CHEK™ test both detect H. pylori in fecal specimens and are substantially equivalent in principle. The following table shows a comparison of both devices.

Predicate Device Comparison TableSimilarities
Item	H. PYLORI QUIK CHEKTM	ImmunoCard STAT!® HpSA (K032222)
Intended Use	The TECHLAB® H. PYLORI QUIK CHEK™test is a rapid membrane enzymeimmunoassay for the qualitative detection ofHelicobacter pylori specific antigen in a singleuse cassette. It is intended for use withhuman fecal specimens to aid in the diagnosisof H. pylori infection and to demonstrate lossof H. pylori antigen following treatment. Thetest can be used with unpreserved fecalspecimens and fecal specimens preserved intransport media from patients suspected of H.pylori infection. Testing of patients todemonstrate loss of H. pylori antigen followingtreatment should be performed no soonerthan 4 weeks after completion of thetreatment regimen. Test results should betaken into consideration by the physician inconjunction with the patient history andsymptoms.	ImmunoCard STAT! HpSA is a rapid invitro qualitative assay for the detection ofHelicobacter pylori antigen in human stool.The stool antigen detection is intended to aidin the diagnosis of H. pylori infection and todemonstrate loss of H. pylori stool antigenfollowing treatment. Conventional medicalpractice recommends that testing by anymethod to confirm the loss of antigen be doneat least four weeks following completion oftherapy.
Measuredanalyte	Detection of H. pylori stool antigen	Detection of H. pylori stool antigen
TargetPopulation	Persons suspected of havingH. pylori infection	Same
Type of Test	Qualitative	Same

{6}------------------------------------------------

Predicate Device Comparison TableSimilarities (continued)
Item	H. PYLORI QUIK CHEK™	ImmunoCard STAT!® HpSA (K032222)
Controls	Positive and negative control included in kitInternal Control line	Same
Storage	Refrigerated (2°C – 8°C)	Same

There are no differences between the subject device and the predicate(s) with respect to indications and intended use.

Predicate Device Comparison TableDifferences
ltem	H. PYLORI QUIK CHEKTM	ImmunoCard STAT!® HpSA (K032222)
Format	Single Use Membrane Cassette25 tests	Single Use Lateral Flow Cassette20 tests
Specimen Type	Fecal Specimens in Cary-Blair and C&STransport Media	Unpreserved Fecal Specimen
Time to Result	30 minutes	5 minutes
Technology	Enzyme Linked Immunoassay (ELISA)	Immunochromatographic (ICT)
Antibody Format	Polyclonal/Polyclonal	Monoclonal/Monoclonal

Summary of Performance Data

The performance of the H. PYLORI QUIK CHEK™ test was evaluated at 6 independent sites. Patients were recruited that were undergoing endoscopy as part of routine care. A composite reference method (CRM) comparison was used in the evaluation consisting of rapid urease and histology of the biopsy samples. The following table shows a summary of the clinical performance data. The results of the study show that the H. PYLORI QUIK CHEK™ test exhibity of 97.0% and specificity 100% with CRM biopsy results.

{7}------------------------------------------------

Age and Gender Distribution

Age and gender information was available for 122 patients. The ages ranged from 19 to 82 years. Of the 122 patients tested, 68% were female and 32% were male. No difference in test performance was observed based on patient age or gender.

Initial Diagnosis H. PYLORI QUIK CHEK™ test versus Composite reference Method (CRM)

N = 122	CRMPositive	CRMNegative
H. PYLORI QUIK CHEK™Positive	32	0
H. PYLORI QUIK CHEK™Negative	1*	89

		95% Confidence Limits
Sensitivity	97.0%	84.7% - 99.5%
Specificity	100.0%	95.9% - 100.0%

*Additional testing with an FDA cleared H. pylori stool antigen teste provided an antigen negative result.

Post-Therapy

For Eradication (post-therapy), there were 9 samples from patients being tested post therapy. The results show that the H. PYLORI QUIK CHEK™ test exhibited a sensitivity of 100% with the composite reference method.

N = 9	CRMPositive	CRMNegative			95% Confidence Limits
H. PYLORI QUIK CHEK™Positive	9	0	Sensitivity	100.0%	70.1% - 100.0%
H. PYLORI QUIK CHEK™Negative	0	0

{8}------------------------------------------------

Retrospective Sample Study

A supplemental retrospective sample study was performed comparing the H. PYLORI QUIK CHEK™ test to an FDA cleared commercial ELISA. For this study, 200 samples (94 positive and 106 negative by the commercial ELISA). There was 98.9% Positive Agreement and 97.2% Negative Agreement of results between the assays.

N = 200	FDA Cleared CommercialELISA Positive	FDA Cleared CommercialELISA Negative
H. PYLORI QUIK CHEK™Positive	93	3*
H. PYLORI QUIK CHEK™Negative	1**	103

		95% Confidence Limits
Percent Positive Agreement	98.9%	94.2% - 99.8%
Percent Negative Agreement	97.2%	92.0% - 99.0%

*H. pylori DNA was amplified from the samples with PCR

**No H. pylori DNA was amplified from the sample with PCR

Reproducibility

The reproducibility of the H. PYLORI QUIK CHEK™ test was determined using 8 fecal specimens that were coded to prevent identification during testing. Testing was performed at 2 independent laboratories and on-site at TECHLAB, Inc. The samples were tested in triplicate twice a day over a 5day period by multiple technicians at each site using 2 different kit lots. The results were as expected among the different locations, and exhibited an overall percent agreement of 100%.

Analytical Sensitivity

The Limit of Detection (LoD) for the H. PYLORI QUIK CHEK™ test was established at 16.08 ng/ml. in fecal matrix (0.24 ng/test) for Helicobacter pylori antigen using cell lysate antigen prepared from H. pylori strain ATCC 43526. For specimens in Protocol™ Cary Blair media, the LoD was established at 13.01 ng/mL (0.20 ng/test). For specimens in Protocol™ C&S media, the LoD was established at 19.96 ng/mL (0.31 ng/test).

Analytical Specificity (Cross Reactivity)

The H. PYLORI QUIK CHEK™ test was evaluated for cross-reactivity with common intestinal organisms and viruses listed below. None of the organisms or viruses were shown to interfere with the performance of the H. PYLORI QUIK CHEK™ test.

Acinetobacter baumannii Borrelia burgdorferi Campylobacter helveticus Campylobacter lari Clostridium bifermentans Edwardsiella tarda

Bacillus cereus Campylobacter coli Campylobacter hyointestinalis Campylobacter upsaliensis Clostridium difficile Enterobacter cloacae

Bacillus subtilis Campylobacter fetus Campylobacter jejuni Candida albicans Clostridium perfringens Enterococcus faecalis

{9}------------------------------------------------

Escherichia coli Escherichia coli ETEC Escherichia coli 0157:H7 (toxigenic) Listeria monocytogenes Prevotella melaninogenica Pseudomonas fluorescens Staphylococcus aureus (Cowan's)

Adenovirus Types 2. 40 Echovirus 9, 22

Escherichia coli EIEC Escherichia coli 0157:H7 (non-toxigenic) Haemophilus influenzae Peptostreptococcus anaerobius Proteus vulgaris Salmonella typhimurium Streptococcus aqalactiae

Human Coronavirus Enterovirus 70

Escherichia coli EPEC Lactobacillus acidophilus Porphyromonas asaccharolytica Pseudomonas aeruginosa Staphylococcus aureus Yersinia enterocolitica

Coxsackievirus B1. B2. B3. B6 Human Rotavirus

Inclusivity Study

The following strains, which include isolates representing described H. pylori populations, were tested for reactivity with the H. PYLORI QUIK CHEK™ test. All strains tested generated a positive result.

ATCC 700392	ATCC 43526	ATCC 700824
JP26	ATCC 43504	ATCC 43579

Interfering Substances (U.S. Formulation)

The following substances had no effect on positive H. PYLORI QUIK CHEK™ test results analyzed at the concentrations indicated:

Barium sulfate (5% w/v), Benzalkonium Chloride (1% w/v), Ciprofloxacin (0.25% w/v), Ethanol (1% w/v), Hog gastric mucin (3.5% w/v), Human blood (40% v/v), Hydrocortisone (1% w/v), Imodium® (5% v/v), Kaopectate® (5% v/v), Leukocytes (0.05% v/v), Maalox® Advanced (5% v/v), Mesalazine (10% w/v), Metronidazole (0.25% w/v), MiraLax® (3350 PEG)(7% w/v), Mineral Oil (10% w/v), Mylanta® (4.2 mq/mL), Naproxen Sodium (5% w/v), Nonoxynol-9 (1% w/v), Palmitic Acid/Fecal Fat (40% w/v), Pepto-Bismo® (5% v/v), Phenvlephrine (1% w/v), Prilosec OTC® (5 µg/mL), Sennosides (1% w/v), Simethicone (10% w/v), Stearic Acid/Fecal Fat (40% w/v), Tagamet® (5 ug/mL), TUMS® (50 µg/mL), Human Urine (5% v/v), and Vancomycin (0.25% w/v).

Prozone

To ensure that a high concentration of H. pylori antigen does not interfere with a positive reaction in the H. PYLORI QUIK CHEK™ test, high positive samples were prepared by spiking a negative fecal pool at concentrations up to 10 times the highest concentration of antigen observed in a positive clinical specimen. A total of 5 different dilutions of H. pylori antigen was prepared and tested in triplicate. The results demonstrated that there was no overall prozone effect, that elevated levels of antigen did not affect the detection of the antigen.

CONCLUSION

The conclusions drawn from the nonclinical and clinical tests demonstrate that the H. PYLORI QUIK CHEK™ test is safe and effective and substantially equivalent to the predicate device in performance. The information submitted in this premarket notification is complete and supports a substantial equivalence decision.

Regulation Number and Section

§ 866.3110

Campylobacter fetus serological reagents.(a)
Identification. Campylobacter fetus serological reagents are devices that consist of antisera conjugated with a fluorescent dye used to identifyCampylobacter fetus from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by this bacterium and provides epidemiological information on these diseases.Campylobacter fetus is a frequent cause of abortion in sheep and cattle and is sometimes responsible for endocarditis (inflammation of certain membranes of the heart) and enteritis (inflammation of the intestines) in humans.(b)
Classification. Class I (general controls).